10-Q: Radnostix Q2 2026: Revenue Drops Amidst Recalls, Debt Restructured

Radnostix Inc. reported a significant decrease in revenue for Q2 2026, driven by product recalls and operational impacts, alongside an increased net loss, though key debt agreements were modified.

Summary

• Radnostix Inc. reported a net loss of $2,230,083 for the six months ended June 30, 2026, a substantial increase from a net loss of $273,479 in the same period of 2025.
• Total sales for the six months ended June 30, 2026, decreased by 27% to $5,050,709 compared to $6,894,220 in the prior year period.
• The Theranostics Products segment experienced a 33% revenue decrease due to two voluntary product recalls (Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules), resulting in an estimated $850,000 in lost revenue.
• The Cobalt Products segment saw a 32% decrease in sales due to an operational shutdown for hot cell rehabilitation.
• Several key promissory note agreements were modified on June 30, 2026, extending maturity dates to March 31, 2031, and introducing new conversion rights.
• The company expects current cash, cash from operations, and potential equity financing to be sufficient for the next twelve months, but acknowledges uncertainty regarding future capital availability.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant revenue declines, increased net losses, and ongoing product recall issues, despite some positive debt restructuring.

Positives

• Several key promissory note agreements (2013, 2018, 2019) were modified on June 30, 2026, extending their maturity dates to March 31, 2031, and introducing voluntary lender and forced borrower conversion rights at a $0.07 conversion price.
• The rehabilitation of Cobalt-60 process hot cell windows and gaskets was completed in Q1 2026, extending the useful life of the equipment by 15-20 years and is estimated to save approximately $150,000 annually in waste costs.
• The company is actively working towards monetizing the NRC license and related assets for the de-conversion facility.
• Disclosure controls and procedures were evaluated and found to be effective as of June 30, 2026.
• Corrective actions for the FDA Form 483 issued in April 2025 have been completed, with a request for inspection closeout submitted on June 19, 2026.

Negatives

• Net loss for the six months ended June 30, 2026, increased significantly to $2,230,083 from $273,479 in the same period of 2025.
• Total sales for the six months ended June 30, 2026, decreased by 27% to $5,050,709 compared to $6,894,220 in the prior year period.
• The Theranostics Products segment experienced a 33% revenue decrease for the six months ended June 30, 2026, largely due to two voluntary product recalls (Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules), resulting in an estimated $850,000 in lost revenue.
• The Cobalt Products segment saw a 32% decrease in sales for the six months ended June 30, 2026, due to an operational shutdown for hot cell rehabilitation.
• The Calibration & Reference Products segment experienced a 17% decrease in sales for the six months ended June 30, 2026, due to an ongoing global shortage of Gadolinium-153.
• Operating expenses increased by 6% for the six months ended June 30, 2026, primarily due to increased stock-based compensation and R&D expenses.
• The company's cash and cash equivalents decreased by approximately 29% to $1,196,492 as of June 30, 2026, from $1,695,158 at December 31, 2025.

Risks

• The FDA could take enforcement actions, including warning letters, penalties, product recalls, or facility suspensions, which could materially adversely affect the business.
• There is a risk of additional FDA action related to the OAI inspection, up to and including a manufacturing and distribution hold or a warning letter.
• The ongoing global shortage of Gadolinium-153 is impacting the Calibration & Reference Products segment, with expected sales to return once supply is restored.
• The company's future liquidity and capital funding requirements depend on numerous factors, and there is no assurance that additional capital will be available on acceptable terms.
• The Theranostics Products segment is subject to risks associated with product recalls and regulatory compliance.
• The production of Cobalt-60 is dependent on the U.S. Department of Energy and its prime operating contractor.
• Sales of Theranostics Products are dependent on a few key suppliers, and an interruption could negatively impact sales.
• The company is subject to ongoing FDA regulations and inspections, and failure to comply could have a material adverse effect.

Future Outlook

The company expects that cash from operations, cash raised via equity financing, and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, and available financing, with no assurance of future capital availability on acceptable terms.

Management Comments

• Management believes it was in the best interest of the shareholders to regain control of the Fluorine Products segment assets as they believe they have appreciated in value.
• Management believes that the company is well positioned to serve the growing radioisotope and radiopharmaceutical market segments.
• Management believes that the rehabilitation work on the Cobalt-60 process hot cell has extended its useful life by 15 to 20 years and will save approximately $150,000 in annual radiological waste costs.
• Management believes that its FDA approved generic sodium iodide I-131 drug product is the only generic product of its type manufactured in the U.S. and offers an attractive domestic alternative.
• Management has evaluated the effectiveness of the registrants disclosure controls and procedures and concluded they were effective as of June 30, 2026.

Industry Context

StockSavvy.ai notes that Radnostix operates in the specialized radioisotope and radiopharmaceutical market, which is experiencing growth, particularly in theranostics. However, the company faces significant challenges including product recalls, regulatory scrutiny from the FDA, and reliance on key suppliers and government entities for raw materials, which are common risks in this highly regulated and specialized industry.

Comparison to Industry Standards

• The theranostics market was valued at $4.3 billion in 2024 and is expected to grow to $12.7 billion by 2029, reflecting a 24% compound annual growth rate, according to BCC Research. Radnostix's Theranostics Products segment is positioned to capitalize on this growth, though current recalls have impacted performance.
• The company's FDA-approved generic sodium iodide I-131 drug product is noted as the only generic product of its type manufactured in the U.S., offering a competitive advantage against foreign manufacturers.
• The Calibration & Reference Products segment competes with a few small regional suppliers internationally and one major global producer. Radnostix differentiates itself through strategic OEM alignment, service, pricing, and exclusive arrangements.
• The company holds a unique combination of high energy and high activity NRC licensing status, compliance with GMP, an FDA licensed operating facility, and experienced personnel, which are key differentiators in the radiopharmaceutical market.

Corporate Governance

Legal Proceedings

• The company is not a party to any legal proceedings and is not aware of any proposed legal proceedings.
• The company may be subject to claims and litigation generally associated with operating in the ordinary course of business.

Related Party Transactions

• The Seventh Modification to the Promissory Note Agreement involves Christopher G. Grosso, Chairman of the Board, acting as executor of the Estate of Ralph M. Richart, a lender.
• The Ninth Modification to the Promissory Note Agreement involves Christopher G. Grosso, Chairman of the Board, acting as Trustee of the Diane H. Grosso Credit Shelter Trust, a lender, and Steve T. Laflin, a board member, as a lender.
• The Fourth Modification to the Promissory Note Agreement involves Christopher G. Grosso, Chairman of the Board, as a lender and executor of the Estate of Ralph M. Richart, and Steve T. Laflin, a board member, as a lender.
• The company borrowed $500,000 on June 23, 2026, from Kershner Grosso & Co., which is managed by the Company's Chairman of the Board.

Stakeholder Impact

• Shareholders may be negatively impacted by the increased net loss and decreased revenue, although the debt restructuring could provide some stability.
• Lenders under the modified promissory notes now have extended maturity dates and new conversion rights, potentially impacting their return on investment.
• Customers may experience continued disruption due to past product recalls, although the company states these have been executed and sales are normalizing.
• Suppliers of key isotopes like Gadolinium-153 face continued demand challenges due to ongoing shortages, impacting Radnostix's supply chain.

Next Steps

• The company is actively working towards monetizing the NRC license and related assets for the de-conversion facility.
• The company plans to explore the feasibility of developing and commercializing IP acquired from Lucerno Dynamics for radiation detection applications.
• The company will continue to execute initiatives designed to strengthen its Quality Management System, with all actions scheduled for completion in July 2026.
• The company will continue to source cobalt-60 from the DOE through amendments to the existing contract.
• The company is working on establishing new suppliers for Gadolinium-153 and expects supply to be restored by the end of 2026.
• The company plans to commercialize additional third-party medical devices and accessories and provide related services.
• The company is continuing the development of its EasyFill Iodine Encapsulation System, targeting a Q1 2027 roll out and Q3 2027 commercial ramp up.

Key Dates

Recommendation

While the debt restructuring and operational improvements in the Cobalt segment are positive, the significant revenue decline, increased net losses, and ongoing product recall issues present substantial headwinds. The company's ability to navigate these challenges and secure future financing remains a key concern. Therefore, a 'hold' recommendation is appropriate pending clearer signs of sustained recovery and resolution of regulatory issues.

Keywords

radioisotope, theranostics, cobalt-60, calibration standards, medical devices, nuclear medicine, promissory note, FDA